Eagle Pharmaceuticals, Inc. today announced that the 505 New Drug Application for its novel pemetrexed drug product has been submitted to the U.S. Food and Drug Administration . "We look forward to the FDA's decision on this NDA this year, and to continuing to work closely with the FDA through the review process.